Institute for Quality and Efficiency in Health Care

Medications

Vortioxetine in depression: No hint of added benefit

Vortioxetine (trade name: Brintellix) has been approved since December 2013 for the treatment of depression in adults, but did not become actually available before May 2015. The German Institute for Quality and Efficiency ...

Medications

Nalmefene for alcohol dependence: Added benefit not proven

Nalmefene (trade name Selincro) has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who do not have physical withdrawal symptoms and who do not require immediate ...

Medications

Safinamide in Parkinson disease: No hint of added benefit

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson ...

Medications

Nivolumab in melanoma: Added benefit in certain patients

Nivolumab (trade name: Opdivo) has been approved since June 2015 for adults with advanced melanoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug ...

Arthritis & Rheumatism

Rheumatoid arthritis: Biologics in second-line therapy show benefit

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined 9 biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis in whom prior pharmacological treatment had failed. ...

page 9 from 29